Jadvar Hossein, Fischman Alan J.
Harvard Medical School Joint Program in Nuclear Medicine, Division of Nuclear Medicine, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
Clin Positron Imaging. 1999 May;2(3):153-158. doi: 10.1016/s1095-0397(99)00014-x.
The purpose of this paper was to evaluate the utility of positron emission tomography (PET) with 2-[18F]fluoro-2-deoxy-D-glucose (FDG) in the clinical assessment of rare tumors. We identified 6 patients over the last 18 months with rare tumors who were referred for PET imaging at the time of initial diagnosis, for tumor surveillance or for posttherapy reevaluation. The PET findings were compared with follow-up clinical data, the results of other imaging modalities and histology. FDG PET correctly detected disease in patients with anaplastic thyroid cancer, pleural mesothelioma, myxoid liposarcoma, malignant fibrous histiocytoma, synovial cell sarcoma and uterine leiomyosarcoma. These findings suggest that PET is useful in the evaluation of a variety of rare tumors both for initial preoperative staging and post-therapy assessment. Further experience with other uncommon tumors is necessary to define the precise role of FDG PET in this clinical setting.
本文的目的是评估采用2-[18F]氟-2-脱氧-D-葡萄糖（FDG）的正电子发射断层扫描（PET）在罕见肿瘤临床评估中的效用。我们在过去18个月里确定了6例患有罕见肿瘤的患者，他们在初始诊断时、肿瘤监测期间或治疗后重新评估时接受了PET成像检查。将PET检查结果与后续临床数据、其他成像方式的结果以及组织学结果进行了比较。FDG PET正确检测出了间变性甲状腺癌、胸膜间皮瘤、黏液样脂肪肉瘤、恶性纤维组织细胞瘤、滑膜细胞肉瘤和子宫平滑肌肉瘤患者的病情。这些发现表明，PET在评估各种罕见肿瘤的术前初始分期和治疗后评估方面均有用处。需要积累更多关于其他罕见肿瘤的经验，以明确FDG PET在这种临床情况下的确切作用。
